Regulatory
FDA Clears Bayer’s Hyrnuo as a First-Line Option for HER2-Mutated Lung Cancer
The accelerated approval lets patients with HER2-mutant non-small cell lung cancer take sevabertinib right away, without needing to try chemotherapy first.